Axicabtagene ciloleucel
Axicabtagene ciloleucel (pronounced ax-i-kab-tag-een sil-oh-loo-sel) is a type of immunotherapy used in the treatment of certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL).
Etymology
The name "Axicabtagene ciloleucel" is derived from the components of the therapy. "Axi-" refers to the CD19 antigen target, "-cabta-" refers to the chimeric antigen receptor (CAR), and "-gene ciloleucel" refers to the genetic modification of the patient's T cells.
Usage
Axicabtagene ciloleucel is used for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Mechanism of Action
Axicabtagene ciloleucel is a CAR T-cell therapy. It works by modifying the patient's own T cells to express a chimeric antigen receptor (CAR) that targets the CD19 antigen, a protein on the surface of B cells, including the cancerous B cells in non-Hodgkin lymphoma.
Related Terms
- Immunotherapy
- Non-Hodgkin lymphoma
- Diffuse large B-cell lymphoma
- Primary mediastinal B-cell lymphoma
- CD19
- Chimeric antigen receptor
- CAR T-cell therapy
External links
- Medical encyclopedia article on Axicabtagene ciloleucel
- Wikipedia's article - Axicabtagene ciloleucel
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski